These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 8801869)

  • 1. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
    Auerbach BJ; Krause BR; Bisgaier CL; Newton RS
    Atherosclerosis; 1995 Jun; 115(2):173-80. PubMed ID: 7661876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
    Aggarwal D; West KL; Zern TL; Shrestha S; Vergara-Jimenez M; Fernandez ML
    BMC Cardiovasc Disord; 2005 Sep; 5():30. PubMed ID: 16188040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
    Bisgaier CL; Essenburg AD; Auerbach BJ; Pape ME; Sekerke CS; Gee A; Wölle S; Newton RS
    J Lipid Res; 1997 Dec; 38(12):2502-15. PubMed ID: 9458274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.
    Conde K; Vergara-Jimenez M; Krause BR; Newton RS; Fernandez ML
    J Lipid Res; 1996 Nov; 37(11):2372-82. PubMed ID: 8978489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat.
    Kasim SE; LeBoeuf RC; Khilnani S; Tallapaka L; Dayananda D; Jen KL
    J Lipid Res; 1992 Jan; 33(1):1-7. PubMed ID: 1552226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet.
    Junquero D; Bruniquel F; N'Guyen X; Autin JM; Patoiseau JF; Degryse AD; Colpaert FC; Delhon A
    Atherosclerosis; 2001 Mar; 155(1):131-42. PubMed ID: 11223434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
    Funatsu T; Kakuta H; Takasu T; Miyata K
    Eur J Pharmacol; 2002 Nov; 455(2-3):161-7. PubMed ID: 12445582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
    Isusi E; Aspichueta P; Liza M; Hernández ML; Díaz C; Hernández G; Martínez MJ; Ochoa B
    Atherosclerosis; 2000 Dec; 153(2):283-94. PubMed ID: 11164417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y; Ishikawa E; Shinozawa E; Shimada M; Miura S; Adachi R; Tozawa R
    Life Sci; 2014 Jul; 108(1):7-12. PubMed ID: 24805868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.